One platform across three species: dogs, cats and horses. Two dog programs are already in clinical trials, and more are on the way.
A therapeutic vaccine that stimulates the dog’s own antibodies against NGF and Substance P, the two mediators of the neurogenic inflammation that sustains osteoarthritis pain.
Clinical trialLearn more → Xep02A therapeutic vaccine that targets the neurogenic inflammation behind chronic itch, with long-lasting control from a few doses a year.
Clinical trialLearn more → Xep01The same immunogen as Xep01, evaluated against the neurogenic inflammation that sustains cancer pain in dogs.
POC clinical trialLearn more → Xep05An immunotherapy designed to neutralize the mediators of neurogenic inflammation in the joint, for long-term pain control in horses.
Pilot safety studyLearn more → Xep03A long-acting immunotherapy adapted to cats, targeting the neurogenic inflammation that keeps osteoarthritis pain going.
Preclinical studiesLearn more → Xep04A long-acting immunotherapy adapted to cats, targeting the neurogenic inflammation behind chronic itch and skin inflammation.
Preclinical studiesLearn more → ExploratoryXeptiva’s technology applied to the immune-metabolic mechanisms of canine obesity.
Target identificationLearn more →